CVL-871

CVL-871

CVL-871

Chemical compound

CVL-871 is a dopamine receptor agonist which is under development for the treatment of dementia-related apathy.[1][2] It was originated by Pfizer and is under development by Cerevel Therapeutics.[1] CVL-871 acts as a selective partial agonist of the dopamine D1 and D5 receptors.[1][2][3] It is taken via oral administration.[1] As of April 2022, CVL-871 is in phase 2 clinical trials for dementia-related apathy.[1]

Quick Facts Clinical data, Routes ofadministration ...

See also

References

  1. [1]
    "CVL 871 - AdisInsight".
  2. [2]
    Hatzipantelis CJ, Langiu M, Vandekolk TH, Pierce TL, Nithianantharajah J, Stewart GD, Langmead CJ (December 2020). "Translation-Focused Approaches to GPCR Drug Discovery for Cognitive Impairments Associated with Schizophrenia". ACS Pharmacol Transl Sci. 3 (6): 1042–1062. doi:10.1021/acsptsci.0c00117. PMC 7737210. PMID 33344888.
  3. [3]
    "CVL-871 - Cerevel Therapeutics". 2 January 2020.



Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article CVL-871, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.